The news directly mentions J&J and its products, Stelara and the Covid-19 vaccine. The potential drop in European sales of Stelara starting mid-2024 could negatively impact the company's revenues, but the overall stability of Stelara sales might offset this. The falling demand for its Covid-19 vaccine, particularly in ex-US markets, could also negatively impact the company's revenues. However, the overall impact on the company's stock price is uncertain in the short term.